Hofseth BioCare ASA: HBC publishes paradigm-changing clinical trial results of OmeGo full spectrum omegas

14 Apr 2026 11:03 CEST

HBC announces the publication of its head-to-head clinical trial results with
its patented, full spectrum omegas brand, OmeGo®. The trial showed that OmeGo®
increased the Omega 3 Index (O3I) by over 70% after 14 weeks, over and above a
popular omega-3 supplement brand. It was also markedly more effective at
reducing inflammatory markers (hsCRP, TNFa and IL-6) which are closely related
to the development of ill health.

The omega-3 index (O3I) assesses the level of EPA and DHA in red blood cells - a
measure known to correlate well with the overall amount of omega-3 in the body.
An optimal O3I level has been shown to reduce the risk of death from any cause
by around 35%. Indeed, a higher O3I is associated with a reduced risk of major
killers including cardiovascular and metabolic disease and cancer.

Notably, OmeGo contains 2.5 times less EPA & DHA than the omega-3 supplement
comparator used in this study. However, its natural food matrix significantly
enhances OmeGo's bioavailability. Hence its full spectrum profile better
replicates the well-known health benefits associated with regularly eating fish.

The success of this clinical study directly challenges the prevailing market
assumption that higher-dose concentrated fish oils deliver greater health
benefits. This represents a paradigm shift in how omega potency is viewed in the
nutraceuticals market.

https://ffhdj.com/index.php/ffhd/article/view/1947/5114

For further information, please contact:
James Berger, CCO at Hofseth BioCare ASA
Phone: +41 79 950 1034
E-mail: jb@hofsethbiocare.no (mailto:jb@hofsethbiocare.no)

About Hofseth BioCare ASA:

HBC is a Norwegian consumer and pet health company founded on the core values of
sustainability, optimal utilization of natural resources and full traceability.
It upcycles the side streams of the salmon industry by taking fresh filleted
salmon and converting it from a waste product into ingredients to improve human
and pet health.

These ingredients are ProGo®, a mix of bioactive peptides and collagen, OmeGo®,
a whole salmon oil, with all the fatty acid fractions contained in fish, and
CalGo® / NT-II® salmon bone powder containing calcium hydroxyapatite and
undenatured collagen for bone and joint health.

HBC places scientific evidence at the forefront which has led to important
academic partnerships and the identification of unique health benefits. This
includes the demonstration of improved iron metabolism by boosting the body's
ability to take up and use iron resulting in increased energy and vitality with
ProGo® as well as the activation of the GLP-1 receptor with fat reduction in
overweight adults. OmeGo® has shown important immune health benefits including
recovery from viral infection and improved respiratory health and sleep in
adults troubled by particulate matter pollution. Finally, CalGo® has shown both
bone and joint health benefits to support healthy ageing and active lifestyles.

This work has also resulted in the granting of several patents protecting these
discoveries. It has also led to the discovery of potential therapeutics and HBC
has spun out a biotech-focused company, HBC Immunology (HBCI) has raised
external finance, and the lead program is in prostate cancer followed by ovarian
cancer. A separate molecule is targeted as an oral, steroid-sparing therapy for
asthma. HBC's headquarters are in Ålesund, Norway with branches in Oslo, London,
Zürich, Los Angeles, and Palo Alto.

HBC is listed on Oslo Stock Exchange with ticker "HBC".

More information:
Access the news on Oslo Bors NewsWeb site